Biogen Finalizes Apellis Takeover Biogen closes its takeover of Apellis, gaining SYFOVRE and EMPAVELI while expanding its rare disease and kidney disease portfolio June 8, 2026 2 min The Ophthalmologist Share Summary Takeaways Listen Insight Report Clinical Scorecard Poll Top Institutions